Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
100%(7 trials)

Phase Distribution

Ph phase_2
4
57%
Ph phase_1
2
29%
Ph phase_3
1
14%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 31 (14.3%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

NCT01515306
completedphase_3

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

NCT00703326
completedphase_2

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

NCT01634555
completedphase_2

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

NCT01427933
completedphase_2

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

NCT00627042
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01515306Phase 2

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Completed
NCT00703326Phase 3

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Completed
NCT01634555Phase 2

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Completed
NCT01427933Phase 2

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Completed
NCT00627042Phase 2

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Completed
NCT01286818Phase 1

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

Completed
NCT01253525Phase 1

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7